IVVD
NASDAQ:IVVDNASDAQ
8 announcements
Credibility Score59%
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
OverhypedModerate hypedeteriorating
Rising revenue is outweighed by surging costs and deepening losses at Invivyd.
33 minutes ago
▼
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
RoutineModerate hypeunclear
Regulatory clock is ticking, but Invivyd offers little substance beyond promises and aspirations.
6 Jul 2026, 11:14 UTC
▼
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
Routineunclear
Invivyd’s update is all about future potential, not present results or revenue.
16 Jun 2026, 11:12 UTC
▼
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
OverhypedModerate hypeunclear
Invivyd hit a trial milestone, but real results and value are years away.
1 Jun 2026, 11:16 UTC
▼
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
OverhypedModerate hypedeteriorating
Revenue is up, but losses are ballooning and real results are still months away.
14 May 2026, 11:19 UTC
▼
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
OverhypedModerate hypeunclear
Invivyd’s tolerability data is promising, but commercial payoff is distant and unproven.
11 May 2026, 11:18 UTC
▼